A global private equity and corporate finance advisory firm is headquartered in Singapore with offices in India, Malaysia and London. The firm makes global investments into life science companies as well as services related to healthcare. The firm leads the round with a $0.5m – $10m investment and utilizes their network to seek out other co-investors. The firm will occasionally seek distribution rights for international investments.

The PE firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, biotech R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country; the firm only looks for companies with a multinational, global component.

The PE firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have assisted scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund with offices in New York and Miami looks to make 3-4 new equity investments into commercial-stage companies located from all geographies, however – the firm likes to see companies with commercial sales in North America and/or Europe. The firm cares less about company headquarters and more about where its products are approved and sold. For companies with enterprise values of $20M – $200M, the firm commits $5M – $20M and is willing to lead rounds or join syndicates as long as the investment gives a meaningful stake in the company for the purposes of being able to add value.

The fund is interested in medical devices and diagnostics. Within medical devices, the firm prefers devices with strong IP protection and generally with PMA or 510(k) approval. Within diagnostics, the firm is very opportunistic though their recent experience has focused on cancer genomic testing. The fund is open to all indication areas but historically has focused on cardiovascular, oncology and minimally invasive surgery.

The fund looks for seasoned management teams that have relevant experience in the sector the company is involved in. The firm likes to see this across the C-suite, particularly in the CEO and sales and marketing leadership. The firm takes a board seat when making investments and looks to add value through active involvement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biopharmaceutical company based in Asia seeks research collaboration, in-licensing, and partnering opportunities with companies mainly in the oncology space. The firm seeks 3-5 projects within the next year. The firm has a “no research, development only” model, and licenses drug candidates ranging from preclinical to clinical stages. The firm currently has projects from the USA and Europe, though is open to projects globally.

The pharma firm seeks biotech therapeutics in oncology and Asian prevalent diseases, such as hepatoma (liver cancer), soft tissue sarcoma, as well as other local diseases in Asia. The firm will consider therapeutics in all phases, and has a particular interest in small biotech companies.

The firm prefers a management team with experience in oncology and other relevant fields of science. As a public company, the firm will partner with the company and collaborate with its research and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture arm of a New Jersey-based merchant bank looks at life science companies that have or are close to acquiring FDA approval, and are now seeking commercial capital. The firm typically leads and co-invests, and will look at early stage companies if the management team is well versed in the specific life science space. The firm typically invests between $5 million and $10 million, and opportunistically invests based on transaction. The firm typically makes 2-3 deals per year, and has invested over $40 million in the past year. The firm currently holds over $60 million in capital. The firm focuses on the east coast of USA, specifically from Boston to Florida, but is also open to Eastern Canada, including Toronto and Montreal.

The firm makes 60% of their activity in medtech devices, including those in healthcare IT and diagnostics. Around 20% of the firm’s activity involves biotech pharmaceuticals and therapeutics. The firm is interested in PMA and 510K medical devices, as well as software-enabled devices and lab equipment and drug development enabling technologies. The firm is open to all diagnostic subsectors—genomics, imaging, and in-vitro—as well as all therapeutic subsectors, though are focused on small molecules. The firm is interested in Phase III to on the market therapeutics, and is interested in medical devices in the development stage that have passed the preliminary design phase with a prototype. The firm has historically invested in assays in cancer diagnostics, as well as devices in the cardiovascular space. The firm is now focusing on opportunities in the pain and neuromodulation space, as well as orthopedics, cancer, and pediatric neurology.

The firm prefers a strong management team that has significant foothold in the space, and has great potential to make good partners. The firm will help fill the management team if necessary, and typically takes a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture capital fund of a large pharmaceutical company is currently investing from its second fund of $100M. The firm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to its parent company. The firm typically invests (equity) $3-$4M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. The firm seeks to make about 2-3 allocations in the next 6-9 months.

The firm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase II. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics and Healthcare IT.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital founded in and based in Hong Kong, Shanghai, Beijing, and Suzhou, China has invested in nearly 50 healthcare companies in China and the U.S. across all sectors of life sciences from pharmaceuticals and medical devices to healthcare IT and diagnostics. The firm typically leads investments, though is also open to co-investing. The firm typically makes equity investments ranging from $1-$35 million, and currently has $1.7 billion in total assets under management, with their latest fund raised in 2014 at $500 million. The firm seeks to make 20-30 new investments within the next year, with a geographical focus in China. The firm is open to opportunities in the US, as the firm recently closed deals in Boston, San Francisco, and Los Angeles.

The firm is open to all sectors and subsectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm mostly invests in 510K devices due to its faster turnaround, but will also invest in devices in the PMA pathway depending on its stage. In therapeutics, the firm is interested in all subsectors including small molecule, biologics, cell therapy, and biosimilars. The firm invests in therapeutics that are past the pre-clinical stage at Phase I to on the market, as well as medical devices that are either at the clinical stage or on the market. The firm is also interested in lab equipment and drug development enabling technologies, and is open to all indications.

The firm prefers a company with a strong management team with experience in the space. The firm will help the company fill spaces in the team if necessary, and will typically take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC fund based in the United States The firm invests in advanced materials technologies across several sectors, including life sciences. The firm is generally a lead investor, and commits up to $8 million per opportunity; investments may be tranched, with an initial commitment of $2-3 million. The firm is open to opportunities globally and has a partner based in Japan, but the firm primarily invests in North America.

The firm is interested in life science companies developing advanced material technologies. In the medtech sector, the firm is oriented toward diagnostic and delivery technologies (including both in vivo and ex vivo delivery); the firm is also interested in advanced materials technologies used in biotech R&D. Areas of interest include biomaterials, drug discovery tools, purification and separation techniques, electrochemistry, nanotechnology, microfluidics, and optics. In diagnostics, the firm is interested in new diagnostic applications of materials science including in sample collection, rapid tests, and biosensors used for real time monitoring; microbiomic diagnostics are also of interest. In addition to the aforementioned areas, the firm is interested in ‘blue sky’ applications of materials science in the life sciences.

The firm does not invest in products that are regulated as therapeutics; in the device space the firm is open to investing in 510k devices, but not PMA devices. However, the firm prefers to invest in technologies that do not require FDA approval. The firm invests in companies that have strong proof of concept data supporting their advanced materials. The firm is open to investing in companies that do not yet have products on the market.

The firm favors companies with partner-based business models, eg. companies developing an enabling technology that a larger partner will deploy to develop a new product. The firm has deep expertise in manufacturing; additionally, LPs include large pharma and medical device manufacturing companies, and the firm helps portfolio companies develop relationships with these strategics.If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com